Harmony Biosciences Holdings, Inc. — Form 8-K/A
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 68/100
What the filing says
Jeffrey M. Dayno, M.D., President and CEO, is separating from Harmony Biosciences effective December 31, 2026, receiving $770,000 severance (12 months base salary), health benefits continuation, 3 months outplacement, earned 2026 bonus, and equity acceleration upon change-in-control. He will serve as paid consultant at $500/hour through January 31, 2028. Simultaneously, Peter Anastasiou is promoted from COO to President and CEO effective January 1, 2027, with base salary of $725,000, target bonus of 75% ($544k), and sign-on equity grants totaling $2.5M ($1.75M options + $750k RSUs, 4-year vest).
Why this rating
CEO departure + promoted replacement is material leadership transition. Dayno severance ~$1-2M total is 0.08–0.15% of $1.3B market cap (routine). Anastasiou's $2.5M sign-on equity is ~0.19% of market cap. Leadership continuity preserved internally; no major business disruption signaled. Moderate significance as CEO change relative to company scale.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.